Literature DB >> 16225471

Review article: steatosis, the metabolic syndrome and cancer.

E Bugianesi1.   

Abstract

The incidence of hepatocellular carcinoma is increasing, but the temporal changes of risk factors remain unclear. A significant proportion of hepatocellular carcinoma (7-30%) develops in cryptogenic cirrhosis, and may represent the most worrisome complication of non-alcoholic steatohepatitis. Non-alcoholic steatohepatitis is tightly related to insulin resistance and several features of the metabolic syndrome, i.e obesity, type 2 diabetes and dyslipidaemia. Nearly two-thirds of adults in the United States and an increasing percentage of the population worldwide are overweight or obese. Diabetes prevalence is increasing as well. The rising prevalence of risk factors associated with non-alcoholic steatohepatitis can partially account for the increasing incidence of cryptogenic cirrhosis and subsequent hepatocellular carcinoma. Moreover, recent evidence demonstrates that both obesity and diabetes are per se associated with an increased cancer risk. Large prospective studies show a significant association with obesity for several cancers, including cancers of the colon, female breast, endometrium, kidney, oesophagus and liver (hepatocellular carcinoma). Type 2 diabetes is also related with increased risks of colon, endometrial, kidney, pancreatic cancer and hepatocellular carcinoma. In western countries, the insulin resistance syndrome is emerging as a risk factor for a wide variety of cancers, including hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225471     DOI: 10.1111/j.1365-2036.2005.02594.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

1.  The pathophysiology of obesity and its clinical manifestations.

Authors:  Richard N Redinger
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-11

2.  Increased age, male gender, and cirrhosis, but not steatosis or a positive viral serology, negatively impact the life expectancy of patients who undergo liver biopsy.

Authors:  Mitchell S Wachtel; Yan Zhang; Kim E Kaye; Maurizio Chiriva-Internati; Eldo E Frezza
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

3.  Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.

Authors:  Manal M Hassan; Steven A Curley; Donghui Li; Ahmed Kaseb; Marta Davila; Eddie K Abdalla; Milind Javle; Dalia M Moghazy; Richard D Lozano; James L Abbruzzese; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2010-04-15       Impact factor: 6.860

4.  The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study.

Authors:  Yuri Cho; Eun Ju Cho; Jeong-Ju Yoo; Young Chang; Goh Eun Chung; In Young Choi; Sang-Hyun Park; Kyungdo Han; Yoon Jun Kim; Jung-Hwan Yoon; Dong Wook Shin; Su Jong Yu
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

Review 5.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

6.  Signal transduction disturbance related to hepatocarcinogenesis in mouse by prolonged exposure to Nanjing drinking water.

Authors:  Rui Zhang; Jie Sun; Yan Zhang; Shupei Cheng; Xiaowei Zhang
Journal:  Environ Sci Pollut Res Int       Date:  2013-04-17       Impact factor: 4.223

Review 7.  Steatocholecystitis and fatty gallbladder disease.

Authors:  Chung-Jyi Tsai
Journal:  Dig Dis Sci       Date:  2008-12-18       Impact factor: 3.199

Review 8.  Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Authors:  J K Dowman; J W Tomlinson; P N Newsome
Journal:  Aliment Pharmacol Ther       Date:  2010-12-29       Impact factor: 8.171

9.  Targeted therapy in hepatocellular carcinoma.

Authors:  Clarinda W L Chua; Su Pin Choo
Journal:  Int J Hepatol       Date:  2011-07-12

Review 10.  Diagnosis and evaluation of nonalcoholic fatty liver disease.

Authors:  Mikako Obika; Hirofumi Noguchi
Journal:  Exp Diabetes Res       Date:  2011-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.